A randomized, double blind, placebo-controlled single ascending dose study on the safety, tolerability, pharmacokinetics and pharmacodynamics of ACT017 in healthy volunteers - ACT-CS-001 (CS0278)

Acticor Biotech SAS0 个研究点目标入组 48 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•1. Males or non-pregnant, non-breastfeeding females, aged *18 and 65 years. Female subjects must be of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation, hysterectomy or bilateral oophorectomy; or as post-menopausal females defined as 12 months amenorrhea and follicle stimulating hormone (FSH) levels >40 IU/L.
•2. Body mass index (BMI) *18 kg/m2 and 30 kg/m2 at screening.
•3. A resting pulse *40 beats per minute (bpm) and *100 bpm at screening and on Day -1.
•4. A resting systolic blood pressure of *150 mmHg and a resting diastolic blood pressure of *95 mmHg at screening and on Day -1.
•5. Baseline laboratory test values within reference ranges based on the blood and urine samples taken at screening and on Day -1. Out of normal ranges values may be accepted by the Investigator, if not clinically significant. Values for hemostasis and coagulation blood test, for bleeding time and platelet aggregation should be normal.

•1. The subject has a history of hemorrhagic disease or venous or arterial thrombotic disease.
•2. The subject has a history or presence of any disorder with an increased risk of bleeding (e.g. ulcus pepticus, hemorrhoids).
•3. The subject has used drugs modifying hemostasis or platelet function within the last month prior to administration of the study drug (i.e. aspirin, antiplatelet drugs, anti-vitamin K drugs and anticoagulant drugs).
•4. The subject has used anti-histamines within the last month prior to administration of the study drug.
•5. The subject has taken prescription or non-prescription medication, herbal remedies, vitamins or minerals within 2 weeks prior to administration of the study drug (or within 5 half-lives prior to administration of the study drug for any medication ingested, whichever is longer).

发起方